<DOC>
	<DOCNO>NCT01393808</DOCNO>
	<brief_summary>Proteinuria independent risk factor cardiovascular morbidity mortality renal disease progression . More proteinuria associate fast progression , whereas treatment reduce proteinuria renoprotective diabetic non diabetic chronic kidney disease . Of note , low residual proteinuria achieve treatment slow disease progression long term . On basis finding , proteinuria become target renoprotective therapy . Among different antihypertensive medication , inhibit Renin Angiotensin System , angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARBs ) , comparable blood pressure control , effectively reduce proteinuria slow renal disease progression . Thus become key component renoprotective therapy patient proteinuric chronic kidney disease . Observational study find effectiveness , however , limit even fully blunt patient eat large amount salt . Experimental evidence indicate renoprotective role vitamin D system chronic renal disease . A recent randomized , control trial , add-on therapy selective Vitamin D receptor activator paricalcitol show additive antiproteinuric effect subject type 2 diabetes chronic kidney disease background Renin-angiotensin-system inhibitor therapy . This effect , however , largely restricted subject daily sodium intake exceed 12 gram negligible low sodium intake . Thus , treatment paricalcitol appear effective particular patient appreciably benefit renin angiotensin system ( RAS ) inhibitor therapy high salt intake . Thus , whether antiproteinuric effect paricalcitol modify concomitant salt intake patient chronic kidney disease ( CKD ) background RAS inhibitor therapy , worth investigating . The broad aim study evaluate interaction paricalcitol therapy sodium intake type 2 diabetes patient proteinuric kidney disease stable background RAS inhibitor therapy .</brief_summary>
	<brief_title>Salt Intake Antiproteinuric Effect Paricalcitol Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Male female patient ; Age &gt; 18 year ; Type 2 diabetes patient low high sodium diet stable RAS inhibitor therapy follow condition : Urinary albumin excretion ( UAE ) rate &gt; 300mg/24 hour ( 200 mcg/min ) ; Serum creatinine &lt; 2 mg/dL , PTH â‰¥ 20 mEq/L &lt; 110 mEq/L ; Calcium phosphorus level &lt; 9.5 mg/dl &lt; 5mg/dl , respectively ; Controlled BP ( systolic/diastolic &lt; 140/90 mmHg ) stable RAS inhibitor therapy ; Written inform consent . Previous Vitamin D Vitamin D analog therapy ( within 3 month prior study entry ) ; Evidence toxicity Vitamin D ; History kidney stone ; Poorly control Diabetes : Hb1Ac &gt; 12 % ; Therapy calcitonin , bisphosphonates , cinacalcet , glucocorticoid , immunosuppressive drug drug may affect calcium bone metabolism ; Cancer severe systemic disease clinical condition may jeopardize data interpretation completion study ; Any clinically relevant condition might affect study participation and/or study result ; Any contraindication expose Paricalcitol ; Pregnancy lactating ; Women childbearing potential without follow scientifically accept form contraception ; Legal incapacity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Paricalcitol</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Sodium intake</keyword>
</DOC>